The global malignant pleural effusion market is expected to garner a market value of US$ 4.5 Billion in 2023 and is expected to accumulate a market value of US$ 8.06 Billion by registering a CAGR of 6% in the forecast period 2023 to 2033. The increasing incidence of pleural effusion disease and rising awareness of advancement in pleural effusion treatment with different types of techniques in the current market works as a driver for the market. The market for Malignant Pleural Effusion registered a CAGR of 4% in the historical period 2018 to 2022.
Clinical examinations and procedures are carried out to diagnose the condition, which aids medical professionals in making additional decisions about medicine, testing, and recuperation and is expected to accelerate market expansion throughout the projection period. Recent epidemiological data from WHO suggests that approximately more than one million pleural effusions are diagnosed in the United States each year.
Report Attribute | Details |
---|---|
Expected Market Value (2023) | US$ 4.5 Billion |
Anticipated Forecast Value (2033) | US$ 8.06 Billion |
Projected Growth Rate (2023 to 2033) | 6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights. the market for Malignant Pleural Effusion reflected a value of 4% during the historical period, 2018 to 2022. Various factors such as awareness in wellness and health, the diagnostics, and pathology segment are improving in developing countries nowadays which grows the therapeutics market. The research and development activities in the field like emerging novel therapeutics, increasing the efficacy of medicine as well as treatment.
Selling campaigns initiated by global players are growing the market progressively. Increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of pleural effusions is fuelling market growth. Thus, the market for Malignant Pleural Effusion is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Increasing Incidence of Malignant Pleural Effusion disease post covid-19 pandemic to push the market growth
The increasing prevalence of Malignant Pleural Effusion disease is one of the biggest drivers of the market. After The covid-19 pandemic hit the world, various research was conducted to find a correlation between Covid-19 infection and pleural effusion.
For instance, the article “Prevalence and Clinical Outcomes of Pleural Effusion in Covid-19 Patients: A Systematic Review and Meta-Analysis” published in January 2022 showed that pleural effusion is related to the risk and prognosis of Covid-19 disease.
Pleural effusion can be used as a prognostic indicator to assess the likelihood of poorer outcomes in Covid-19 patients; as a result, the researchers of the above-mentioned research article advised that hospitalized Covid-19 patients with pleural effusion be handled promptly. Considering these in-depth studies, the pandemic showed a considerable impact on the market studied.
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Malignant Pleural Effusion, less awareness of Malignant Pleural Effusion disease, and insubstantial treatment options are hampering the market growth.
Improvement in healthcare spending propelling the growth of Malignant Pleural Effusion in Asia Pacific
The Asia Pacific is expected to exhibit the fastest growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of malignant pleural effusion in the region.
Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the Pleural effusions treatment market worldwide.
High Prevalence of various diseases shaping the landscape for Malignant Pleural Effusion in North America
North America is anticipated to acquire a market share of about 45% in the forecast period. This growth is attributable to the rising prevalence of pleural effusions in the region. An article published by WebMD LLC in October 2021 stated that approximately 1.5 million pleural effusions are diagnosed in the United States every year and in industrialized countries, the estimated prevalence of pleural effusion is 320 cases per 100,000 people.
This ever-widening burden of the condition on the healthcare facilities is creating demand for the treatment globally, expected to fuel the market growth during the analysis period. Furthermore, the rising geriatric population is leading to an increase in the prevalence of various diseases, growing the health and economic burden.
As per the American Heart Association data updated in April 2022, nearly 115 million people in have hypertension, 100 million have obesity, 92 million have prediabetes, 26 million have diabetes, and 125 million have atherosclerotic cardiovascular diseases (CVD) United States, which are known to be the risk factors for the development of heart failure. Thus, the high burden of various diseases creates the risk of pleural effusions among the target population in the United States.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key start-up players in the Malignant Pleural Effusion market are-
Key players in the Malignant Pleural Effusion market are Allakos, iCo Therapeutics, Akari Therapeutics, and Santen.
Report Attribute | Details |
---|---|
Market Value in 2023 | US$ 4.5 Billion |
Market Value in 2033 | US$ 8.06 Billion |
Growth Rate | CAGR of 6% from 2023 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in US$ Million and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
From 2017 to 2022, the Malignant Pleural Effusion market grew at a CAGR of 4%.
The global Malignant Pleural Effusion market is expected to grow with a 6% CAGR from 2023 to 2033.
As of 2033, the Malignant Pleural Effusion market is expected to reach US$ 8.06 Billion
According to the FMI analysis, hospitals account for the largest market share.
North America is expected to possess a 45% market share for the Malignant Pleural Effusion market.
The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
1. Executive Summary | Malignant Pleural Effusion Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033 5.3.1. Imaging Tests 5.3.2. Pleural Thoracocentesis 5.3.3. Pleural Fluid Cytology 5.3.4. Immunohistochemical Tests 5.3.5. Pleural Biopsy 5.3.6. Thoracoscopy/Pleuroscopy 5.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 6.3.1. Systemic Therapy 6.3.2. Therapeutic Thoracentesis 6.3.3. Thoracic Drainage and Pleurodesis 6.3.4. Indwelling Pleural Catheter 6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 7.3.1. Hospitals 7.3.2. Ambulatory Clinics 7.3.3. Others 7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. Asia-Pacific 8.3.6. Middle East & Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The US 9.2.1.2. Canada 9.2.2. By Diagnosis 9.2.3. By Treatment 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Diagnosis 9.3.3. By Treatment 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Diagnosis 10.2.3. By Treatment 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Diagnosis 10.3.3. By Treatment 10.3.4. By End User 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Benelux 11.2.1.2. France 11.2.1.3. Germany 11.2.1.4. Italy 11.2.1.5. Nordic 11.2.1.6. Spain 11.2.1.7. The UK 11.2.1.8. Rest of Western Europe 11.2.2. By Diagnosis 11.2.3. By Treatment 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Diagnosis 11.3.3. By Treatment 11.3.4. By End User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Rest of Eastern Europe 12.2.2. By Diagnosis 12.2.3. By Treatment 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Diagnosis 12.3.3. By Treatment 12.3.4. By End User 12.4. Key Takeaways 13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Australia 13.2.1.6. New Zealand 13.2.1.7. Rest of APAC 13.2.2. By Diagnosis 13.2.3. By Treatment 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Diagnosis 13.3.3. By Treatment 13.3.4. By End User 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Diagnosis 14.2.3. By Treatment 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Diagnosis 14.3.3. By Treatment 14.3.4. By End User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. U.S. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Diagnosis 15.1.2.2. By Treatment 15.1.2.3. By End User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Diagnosis 15.2.2.2. By Treatment 15.2.2.3. By End User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Diagnosis 15.3.2.2. By Treatment 15.3.2.3. By End User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Diagnosis 15.4.2.2. By Treatment 15.4.2.3. By End User 15.5. Benelux 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Diagnosis 15.5.2.2. By Treatment 15.5.2.3. By End User 15.6. France 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Diagnosis 15.6.2.2. By Treatment 15.6.2.3. By End User 15.7. Germany 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Diagnosis 15.7.2.2. By Treatment 15.7.2.3. By End User 15.8. Italy 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Diagnosis 15.8.2.2. By Treatment 15.8.2.3. By End User 15.9. Nordic 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Diagnosis 15.9.2.2. By Treatment 15.9.2.3. By End User 15.10. Spain 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Diagnosis 15.10.2.2. By Treatment 15.10.2.3. By End User 15.11. The UK 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Diagnosis 15.11.2.2. By Treatment 15.11.2.3. By End User 15.12. Poland 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Diagnosis 15.12.2.2. By Treatment 15.12.2.3. By End User 15.13. Russia 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Diagnosis 15.13.2.2. By Treatment 15.13.2.3. By End User 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Diagnosis 15.14.2.2. By Treatment 15.14.2.3. By End User 15.15. Malaysia 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Diagnosis 15.15.2.2. By Treatment 15.15.2.3. By End User 15.16. Singapore 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Diagnosis 15.16.2.2. By Treatment 15.16.2.3. By End User 15.17. Thailand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Diagnosis 15.17.2.2. By Treatment 15.17.2.3. By End User 15.18. Australia 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Diagnosis 15.18.2.2. By Treatment 15.18.2.3. By End User 15.19. New Zealand 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Diagnosis 15.19.2.2. By Treatment 15.19.2.3. By End User 15.20. GCC Countries 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Diagnosis 15.20.2.2. By Treatment 15.20.2.3. By End User 15.21. South Africa 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Diagnosis 15.21.2.2. By Treatment 15.21.2.3. By End User 15.22. Israel 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Diagnosis 15.22.2.2. By Treatment 15.22.2.3. By End User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Diagnosis 16.3.3. By Treatment 16.3.4. By End User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. B. Braun SE 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Becton, Dickinson, and Company 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Bicakcilar 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Biometrix 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Cook Medical 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Grena 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Redax 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Rocket Medical 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Smith Medical 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Taiho Pharmaceutical Co., Ltd 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports